



Regular Meeting of the
Santa Clara County Health Authority d.b.a. Santa Clara Family Health Plan
OPEN SESSION - Pharmacy & Therapeutics Committee

Thursday, March 15, 2018
 6:00 PM - 8:00 PM
 210 E. Hacienda Avenue Campbell, CA 95008

MINUTES

Voting Committee Members	Specialty	Present (Y or N)
Jimmy Lin, MD	Internal Medicine	Y
Hao Bui, BS, PharmD	Community Pharmacy (Walgreens)	N
Minh Thai, MD	Family Practice	Y
Amara Balakrishnan, MD	Pediatrics	Y
Peter Nguyen, MD	Family Practice	Y
Jesse Parashar-Rokicki, MD	Family Practice	Y
Narinder Singh, PharmD	Health System Pharmacy (SCVMC)	N
Ali Alkoraishi, MD	Adult & Child Psychiatry	Y
Dolly Goel, MD	VHP Chief Medical Officer	Y
Xuan Cung, PharmD	Pharmacy Supervisor (VHP)	N
Johanna Liu, PharmD, MBA	SCFHP Director of Quality and Pharmacy	Y
Jeff Robertson, MD	SCFHP Chief Medical Officer	Y

Non-Voting Committee Members	Specialty	Present (Y or N)
Lily Boris, MD	SCFHP Medical Director	N
Caroline Alexander	SCFHP Administrative Assistant, Medical Management	N
Tami Otomo, PharmD	SCFHP Clinical Pharmacist	Y
Duyen Nguyen, PharmD	SCFHP Clinical Pharmacist	Y
Dang Huynh, PharmD	SCFHP Pharmacy Manager	Y
Amy McCarty, PharmD	MedImpact Clinical Program Manager	Y
Tiffanie Pham, CPhT	SCFHP Pharmacy Coordinator	Y

	Topic and Discussion	Follow-Up Action
1	Introductions The meeting convened at 6:09 PM.	
2	Public Comment No public comment.	
3	Past Meeting Minutes The SCFHP 4Q2017 P&T Minutes from December 14, 2017 were reviewed by the Committee as submitted.	Upon motion duly made and seconded, the SCFHP 4Q2017 P&T Minutes from December 14, 2017 were approved as



		submitted and will be forwarded to the QI Committee and Board of Directors.
4	Plan Updates	
	<p>Health Plan Updates Dr. Robertson presented the slow, but steady decline in Medi-Cal members possibly due to the actions of immigration rates. The annual DHCS audit will be held next month from 4/9-4/20 at the health plan.</p> <p>Dr. Peter Nguyen asked if the steady decline was affecting the Medicare or Medi-Cal line of business. Dr. Robertson clarified that this is affecting the Medi-Cal line of business, and Medicare line of business is increasing.</p>	
	<p>Appeals & Grievances Dr. Huynh presented the Appeals & Grievances report Q4 2017. There was a decline in Medi-Cal appeals after a short increase due to a change in process. Q4 2017 53% overturn rate, 27% upheld, 5% withdrawn. For CalMediConnect (CMC), Q3-Q4 Part C&D redeterminations have remained steady. Redeterminations Q4, 39% overturned, 56% upheld, 0% withdrawn.</p> <p>Dr. Peter Nguyen asked if the percentages are normal compared to other health plans, and Dr. Robertson clarified that SCFHP does not have available data to benchmark our results to.</p>	
	<p>SCFHP Pharmacy Dept. Policies: Dr. Huynh presented the Pharmacy Dept. Policies as followed:</p> <ol style="list-style-type: none"> 1. PH01 Pharmacy and Therapeutics Committee 2. PH02 Formulary Development and Guideline Management 3. PH03 Prior Authorization 4. PH04 Pharmacy Clinical Programs and Quality Monitoring 5. PH05 Continuity of Care for Pharmacy Services 6. PH06 Pharmacy Communications 7. PH07 Drug Recalls 8. PH08 Pain Management Drugs for Terminally Ill 9. PH09 Medications for Members with Behavioral Health Conditions – <i>Revised</i> 10. PH10 Cal MediConnect Part D Transition 11. PH11 340B Program Compliance 12. PH14 Medications for Cancer Clinical Trial 	Upon motion duly made and seconded, the Pharmacy Dept. Policies were approved as presented.
	<p>Adjourn to Closed Session Committee adjourned to closed session at 6:20 p.m. to discuss the following items: Membership Report, Pharmacy Dashboard, Drug Use</p>	



	Evaluation Results, Drug Utilization & Spend, Recommendations for Changes to SCFHP Cal MediConnect Formulary and Prior Authorization Criteria, Recommendations for changes to Medi-Cal and Healthy Kids Formulary and Prior Authorization Criteria, DHCS Medi-Cal CDL Updates & Comparability, and New Drugs.	
5	Metrics & Financial Updates	
	Membership Report Dr. Robertson presented the membership report.	
	Pharmacy Dashboard Dr. Otomo presented the Pharmacy Dashboard.	
	Drug Utilization & Spend Review Dr. McCarty presented the Drug Use Evaluation Results.	
	Drug Utilization & Spend Review Dr. McCarty presented the Spend and Trend Overview.	
6	Discussion and Recommendations for changes to SCFHP Cal MediConnect Formulary & Prior Authorization Criteria	
	Dr. Huynh presented an overview of the MedImpact 4Q2017 P&T minutes as well as the MedImpact 1Q2018 P&T Part D Actions.	Upon motion duly made and seconded the MedImpact 4Q2017 P&T Minutes, and MedImpact 1Q2018 P&T Part D Actions were approved as submitted.
7	Discussion and Recommendations for Changes to SCFHP Medi-Cal & Healthy Kids Formulary & Prior Authorization Criteria	
	Formulary Modifications Dr. Otomo presented the formulary changes since the last P&T meeting.	Upon motion duly made and seconded, formulary modifications were approved as presented.
	DHCS Medi-Cal CDL Updates & Comparability Dr. McCarty presented DHCS Medi-Cal CDL Updates & Comparability.	Upon motion duly made and seconded, prior authorization criteria were approved as requested.
	Prior Authorization Criteria Dr. Duyen Nguyen presented the following PA criteria for approval by the committee: <ol style="list-style-type: none"> 1. Zetia 2. Glatiramer acetate 	Upon motion duly made and seconded, prior authorization criteria were approved with the requested deletion from the Oncology PA criteria.



	<ol style="list-style-type: none">3. Oncology4. Quantity Limit	
	<p>New Drugs and Class Reviews Dr. McCarty presented the following new drug reviews:</p> <ol style="list-style-type: none">1. Diabetes Update SGLT-2 inhibitors, Rapid Acting Insulin.2. Hemlibra.3. Psoriasis Update – Tildrakizumab.	Upon motion duly made and seconded, all recommendations were approved as presented.
	<p>Reconvene in Open Session Committee reconvened to open session at 7:44 p.m.</p>	
8	Discussion Items	
	<p>Update on New Drugs and Generic Pipeline Dr. McCarty presented the generic pipeline for 1Q2018. High impact drugs: ProAir HFA, Tracleer, Byetta, Sensipar and medium/low impact drugs: Forfivo, XL, Viread, Solodyn, Treximet, Zortress, and Sustiva.</p>	
9	Adjournment at 7:49 PM	